The Senate Finance Committee today held a hearing for Alex Azar, President Trump’s nominee for secretary of Health and Human Services. Azar, former president of Lilly USA and deputy HHS secretary under the George W. Bush administration, faced a number of questions from senators about his ties to the pharmaceutical industry and how he would tackle high drug prices. If confirmed, Azar said he would focus his efforts on addressing the high cost of drugs; making health care more affordable, available and “tailored to what individuals want and need in their care”; harnessing “the power of Medicare to shift the focus in our health care system from paying for procedures and sickness to paying for health and outcomes”; and tackling “the scourge of the opioid epidemic.” Tom Price, M.D., resigned as HHS secretary last September. Deputy Secretary Eric Hargan has been serving as acting secretary.

Related News Articles

Headline
Continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and…
Headline
AHA said it generally supports CMS’ efforts to grant greater state-level flexibility and reduce regulatory burden, but urged the agency to ensure Medicaid…
Headline
Virginia hospitals and health systems provided nearly $3.3 billion in community benefit and other support in 2017, according to the latest annual report by the…
Perspective
We’re 11 days into 2019 … we’ve returned to a divided government …and the partial government shutdown continues.
Headline
The House of Representatives last night authorized its general counsel to intervene to defend the Affordable Care Act in a federal court case in Texas, and in…
Insights and Analysis
The secret to healthy, long lives lies in their social determinants. Six hospitals in a vulnerable area of Chicago pooled resources and ideas to address those…